文献速递中医内科中药与中成药合理使用

口服中成药乌蛇止痒丸通过调控ALOX15衍生的氧化脂质紊乱缓解特应性皮炎

Oral Chinese patent medicine alleviates atopic dermatitis by regulating ALOX15-derived oxylipins disorder.
PubMed 文献 · Phytomedicine · 2026-07-02

本研究在DNCB诱导的小鼠特应性皮炎模型上,结合慢性束缚应激模拟心理压力,评估乌蛇止痒丸的保护作用及机制。结果表明乌蛇止痒丸能改善AD样症状、恢复Th1/Th2平衡、降低IgE,并逆转应激诱导的ALOX15上调及氧化脂质紊乱;升麻素为其直接抑制ALOX15的活性成分。

要点

  • 乌蛇止痒丸可改善应激加重的小鼠AD样症状及免疫失衡。
  • 心理应激通过上调ALOX15及15-HETE等促炎介质加重AD。
  • 升麻素是乌蛇止痒丸中直接抑制ALOX15的活性成分。

核心结论

  • 乌蛇止痒丸通过抑制ALOX15介导的氧化脂质紊乱缓解应激加重的AD,升麻素为关键活性成分。
  • 研究揭示「应激-ALOX15-氧化脂质-炎症」轴,支持乌蛇止痒丸用于应激相关AD。

研究设计与样本

  • 采用重复DNCB涂抹建立小鼠AD模型,并联合慢性束缚应激模拟心理压力暴露。
  • 综合评估AD样表型严重度、免疫功能障碍及炎症反应。
  • 采用靶向氧化脂质组学分析脂质介质变化,并用分子对接、分子动力学模拟和细胞热位移分析(CETSA)鉴定并验证直接靶点及活性成分。

主要发现

  • 乌蛇止痒丸治疗显著改善AD样症状,恢复Th1/Th2免疫平衡,减少肥大细胞浸润和皮肤炎症细胞因子表达,并降低血清IgE水平。
  • 心理应激通过上调ALOX15表达、破坏皮肤氧化脂质谱并显著升高15-HETE等促炎介质加重AD。
  • 乌蛇止痒丸有效逆转应激诱导的氧化脂质紊乱。
  • 升麻素被鉴定为乌蛇止痒丸中直接抑制ALOX15的活性成分,可稳定结合并抑制其活性,恢复氧化脂质稳态。

临床怎么用

  • 对伴有心理应激因素的特应性皮炎患者,可考虑在辨证基础上选用乌蛇止痒丸。
  • 其作用机制与抑制ALOX15、降低15-HETE等促炎氧化脂质相关,可作为选药参考。

局限性

  • 研究基于小鼠AD模型,临床疗效与人体适用性尚需进一步验证。
  • 心理应激采用慢性束缚应激模拟,与人类心理应激状态存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease often exacerbated by psychological stress, yet the underlying mechanisms remain unclear. Wushe Zhiyang Pills (WZP), an oral Chinese patent medicine, is clinically used for dermatological conditions, but its efficacy and mechanisms in stress-aggravated AD have not been defined. PURPOSE: This study aims to evaluate the protective effects of WZP against AD under stress conditions, elucidate its molecular mechanisms, and identify its bioactive compounds. METHODS: A murine AD model was established using repeated DNCB application, with or without chronic restraint stress to simulate psychological stress exposure. AD-like phenotypic severity, immune dysfunction, and inflammatory responses were comprehensively assessed. Targeted oxylipin lipidomics was performed to profile lipid mediator alterations, while molecular docking, molecular dynamics simulations, and cellular thermal shift assays (CETSA) were employed to identify and validate the direct target and active components of WZP. RESULTS: WZP treatment significantly ameliorated AD-like symptoms, restored the Th1/Th2 immune balance, reduced mast cell infiltration and cutaneous inflammatory cytokine expression, and lowered serum IgE levels. Notably, psychological stress exacerbated AD by upregulating ALOX15 expression and disrupting the cutaneous oxylipin profile, with marked elevations in pro-inflammatory mediators such as 15-HETE. WZP effectively reversed these stress-induced oxylipin derangements. Mechanistically, cimifugin, a bioactive component of WZP, was identified as a direct inhibitor of ALOX15, binding stably to the enzyme and suppressing its activity, thereby restoring oxylipin homeostasis. CONCLUSION: WZP alleviates stress-aggravated AD by inhibiting ALOX15-mediated oxylipin disruption, with cimifugin as a key active component. This reveals a novel "Stress-ALOX15-oxylipin-inflammation" axis and supports WZP as a promising therapy for stress-associated AD.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Ru N, Guo MZ, Xu H, et al. Oral Chinese patent medicine alleviates atopic dermatitis by regulating ALOX15-derived oxylipins disorder. Phytomedicine. 2026. PMID: 42447509. doi:10.1016/j.phymed.2026.158524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。